ME02765B - (z)-2-cijan0-3-hidroksi-but-2-enske kiseline (4'-trifluormetilfenil) -amid formulacije tableta sa poboljšanom stabilnošću - Google Patents

(z)-2-cijan0-3-hidroksi-but-2-enske kiseline (4'-trifluormetilfenil) -amid formulacije tableta sa poboljšanom stabilnošću

Info

Publication number: ME02765B
Authority: ME; Montenegro
Prior art keywords: amid; trifluoromethylphenyl; cyano; hydroxy; acid
Prior art date: 2009-09-18

Application number

MEP-2017-134A

Other languages

German (de)

English (en)

French (fr)

Inventor

Gerrit Hauck

Original Assignee

Sanofi Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2009-09-18

Filing date

2010-09-14

Publication date

2018-01-20

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41510564&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME02765(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2010-09-14 Application filed by Sanofi Sa filed Critical Sanofi Sa

2018-01-20 Publication of ME02765B publication Critical patent/ME02765B/me

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
- C07C255/44—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Oncology (AREA)
Hematology (AREA)
Diabetes (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Neurosurgery (AREA)
Obesity (AREA)
Otolaryngology (AREA)
Neurology (AREA)
Transplantation (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Nutrition Science (AREA)
Inorganic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

MEP-2017-134A 2009-09-18 2010-09-14 (z)-2-cijan0-3-hidroksi-but-2-enske kiseline (4'-trifluormetilfenil) -amid formulacije tableta sa poboljšanom stabilnošću ME02765B (me)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
EP09290716		2009-09-18
US36338210P	2010-07-12	2010-07-12
EP10752585.9A EP2477611B1 (en)	2009-09-18	2010-09-14	(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability
PCT/EP2010/063439 WO2011032929A1 (en)	2009-09-18	2010-09-14	(z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability

Publications (1)

Publication Number	Publication Date
ME02765B true ME02765B (me)	2018-01-20

Family

ID=41510564

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MEP-2017-134A ME02765B (me)	2009-09-18	2010-09-14	(z)-2-cijan0-3-hidroksi-but-2-enske kiseline (4'-trifluormetilfenil) -amid formulacije tableta sa poboljšanom stabilnošću

Country Status (41)

Country	Link
US (5)	US20120172427A1 (me)
EP (1)	EP2477611B1 (me)
JP (1)	JP2013505213A (me)
KR (1)	KR101547880B1 (me)
CN (4)	CN104739821B (me)
AR (1)	AR078383A1 (me)
AU (2)	AU2010297357B2 (me)
BR (1)	BR112012006184B1 (me)
CA (1)	CA2772275A1 (me)
CL (1)	CL2015000047A1 (me)
CO (1)	CO6511244A2 (me)
CR (2)	CR20170078A (me)
CY (1)	CY1119364T1 (me)
DK (1)	DK2477611T3 (me)
DO (1)	DOP2012000070A (me)
ES (1)	ES2625731T3 (me)
GT (1)	GT201200075A (me)
HK (2)	HK1206245A1 (me)
HN (1)	HN2012000576A (me)
HR (1)	HRP20170904T1 (me)
HU (1)	HUE032963T2 (me)
IL (3)	IL218492A (me)
JO (1)	JO3327B1 (me)
LT (1)	LT2477611T (me)
MA (1)	MA33585B1 (me)
ME (1)	ME02765B (me)
MX (1)	MX336663B (me)
MY (1)	MY155613A (me)
NZ (2)	NZ598744A (me)
PE (2)	PE20152031A1 (me)
PL (1)	PL2477611T3 (me)
PT (1)	PT2477611T (me)
RS (1)	RS56074B1 (me)
RU (2)	RU2012115459A (me)
SI (1)	SI2477611T1 (me)
SM (1)	SMT201700299T1 (me)
TN (1)	TN2012000061A1 (me)
TW (2)	TWI522130B (me)
UA (2)	UA107582C2 (me)
UY (1)	UY32889A (me)
WO (1)	WO2011032929A1 (me)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN104739821B (zh) *	2009-09-18	2018-04-06	赛诺菲	稳定性提高的(z)‑2‑氰基‑3‑羟基‑丁‑2‑烯酸‑(4’‑三氟甲基苯基)‑酰胺片剂制剂
RU2493845C1 (ru) *	2012-06-07	2013-09-27	Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ"	Композиция для лечения рассеянного склероза (варианты)
KR20160079123A (ko) *	2013-11-22	2016-07-05	젠자임 코포레이션	신경변성 질병을 치료하기 위한 신규한 방법
CN103656657A (zh) *	2013-12-18	2014-03-26	北京科源创欣科技有限公司	特立氟胺药物组合物及制备方法
PT3122358T (pt)	2014-03-26	2021-03-04	Astex Therapeutics Ltd	Combinações de inibidores do fgfr e cmet para o tratamento do cancro
US20160058730A1 (en) *	2014-08-29	2016-03-03	Cadila Healthcare Limited	Pharmaceutical compositions of teriflunomide
WO2016079687A1 (en) *	2014-11-18	2016-05-26	Lupin Limited	Oral pharmaceutical composition of teriflunomide
JOP20200201A1 (ar)	2015-02-10	2017-06-16	Astex Therapeutics Ltd	تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US20180147148A1 (en)	2015-05-23	2018-05-31	Ftf Pharma Private Limited	Pharmaceutical composition of teriflunomide
EP3344243B1 (en) *	2015-09-01	2020-12-09	The Broad Institute, Inc.	Compounds and methods useful for treating or preventing hematological cancers
WO2017037645A1 (en) *	2015-09-02	2017-03-09	Leiutis Pharmaceuticals Pvt Ltd	Stable pharmaceutical formulations of teriflunomide
WO2017056104A1 (en) *	2015-09-28	2017-04-06	Natco Pharma Limited	Stable pharmaceutical compositions of teriflunomide
WO2017125841A1 (en) *	2016-01-20	2017-07-27	Emcure Pharmaceuticals Limited	Pharmaceutical compositions of teriflunomide
JOP20190207A1 (ar)	2017-03-14	2019-09-10	Actelion Pharmaceuticals Ltd	تركيبة صيدلانية تشتمل على بونيسيمود
AU2020315642A1 (en) *	2019-07-17	2022-03-03	Cytokinetics, Inc.	Cardiac sarcomere inhibitor oral formulations
EP4178548B1 (en) *	2020-07-07	2024-07-24	Celgene Corporation	Pharmaceutical compositions comprising (s)-4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)oxy)m ethyl) benzyl)piperazin-1-yl)-3-fluorobenzonitrile and methods of using the same
WO2022085015A1 (en) *	2020-10-24	2022-04-28	V-Ensure Pharma Technologies Private Limited	A solid oral composition of teriflunomide
GR1010137B (el)	2020-12-15	2021-12-07	Φαρματεν Α.Β.Ε.Ε.,	Στερεη φαρμακοτεχνικη μορφη αμεσης αποδεσμευσης περιεχουσα τεριφλουνομιδη και μεθοδος παρασκευης αυτης
TR202022336A2 (tr) *	2020-12-30	2022-07-21	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	A film coated tablet comprising teriflunomide
WO2024112298A1 (en) *	2022-11-25	2024-05-30	Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi	A tablet comprising teriflunomide
EP4382097A1 (en)	2022-11-25	2024-06-12	Sanovel Ilac Sanayi Ve Ticaret A.S.	A tablet comprising teriflunomide

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3852294A (en) *	1968-08-27	1974-12-03	Merck Patent Gmbh	Bis-quaternary pyridinium salts
DE3534440A1 (de)	1985-09-27	1987-04-02	Hoechst Ag	Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes
US5268382A (en)	1985-09-27	1993-12-07	Hoechst Aktiengesellschaft	Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
US6133301A (en)	1991-08-22	2000-10-17	Aventis Pharma Deutschland Gmbh	Pharmaceuticals for the treatment of rejection reactions in organ transplantations
US5700823A (en)	1994-01-07	1997-12-23	Sugen, Inc.	Treatment of platelet derived growth factor related disorders such as cancers
GB9408117D0 (en) *	1994-04-23	1994-06-15	Smithkline Beecham Corp	Pharmaceutical formulations
PT787491E (pt)	1994-10-17	2000-11-30	Aventis Pharma Ltd	Composicao para a profilaxia e para o tratamento de doencas alergicas de tipo i
PT987256E (pt)	1997-08-08	2002-03-28	Aventis Pharma Gmbh	Forma cristalina da n-(4-trifluorometilfenil)-5-metil-isoxazol-4-carboxamida
US6248363B1 (en) *	1999-11-23	2001-06-19	Lipocine, Inc.	Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
DE60110043T2 (de)	2000-02-15	2006-03-02	Teva Pharmaceutical Industries Ltd.	Methode zur synthetisierung von leflunomid
WO2002080897A1 (en) *	2001-04-05	2002-10-17	Aventis Pharmaceuticals Inc.	Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
GB0123571D0 (en) *	2001-04-05	2001-11-21	Aventis Pharm Prod Inc	Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
US20050158371A1 (en)	2002-02-12	2005-07-21	Sumitomo Pharmaceuticals Co., Ltd.	Novel external agent
CA2536175C (en) *	2003-08-29	2013-05-28	Transform Pharmaceuticals, Inc.	Pharmaceutical compositions and method of using levodopa and carbidopa
GB2394660A (en)	2003-12-17	2004-05-05	Niche Generics Ltd	Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide
US20050220874A1 (en) *	2004-04-02	2005-10-06	Chien-Hsuan Han	Pharmaceutical dosage forms having immediate release and controlled release properties that contain a GABAB receptor agonist
US20060024376A1 (en) *	2004-07-30	2006-02-02	The University Of Chicago	Methods and compositions for reducing toxicity associated with leflunomide treatment
CN101043883A (zh) *	2004-10-19	2007-09-26	安万特药物公司	(z)－2－氰基－3－羟基－丁－2－烯酸－(4'－三氟甲基苯基)－酰胺用于治疗炎症性肠病的用途
TWI275029B (en) *	2005-11-18	2007-03-01	Hon Hai Prec Ind Co Ltd	An embedded system and method for processing data thereof
CA2637925A1 (en)	2006-01-24	2007-08-02	Teva Pharmaceutical Industries Ltd.	Levetiracetam formulations and methods for their manufacture
DE102006017896A1 (de) *	2006-04-13	2007-10-25	Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg	Leflunomid enthaltende pharmazeutische Zusammensetzungen
EP1990048A3 (en)	2007-05-08	2009-05-06	Ulrike Wiebelitz	Therapy of benign prostatic hyperplasia (bph)
CN104739821B (zh) *	2009-09-18	2018-04-06	赛诺菲	稳定性提高的(z)‑2‑氰基‑3‑羟基‑丁‑2‑烯酸‑(4’‑三氟甲基苯基)‑酰胺片剂制剂
EP2762135A1 (en) *	2013-02-04	2014-08-06	Sanofi	Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients

2010
- 2010-09-14 CN CN201510052299.XA patent/CN104739821B/zh not_active Ceased
- 2010-09-14 PL PL10752585T patent/PL2477611T3/pl unknown
- 2010-09-14 SI SI201031476A patent/SI2477611T1/sl unknown
- 2010-09-14 PE PE2015002059A patent/PE20152031A1/es active IP Right Grant
- 2010-09-14 MX MX2012003122A patent/MX336663B/es unknown
- 2010-09-14 NZ NZ598744A patent/NZ598744A/xx unknown
- 2010-09-14 BR BR112012006184-4A patent/BR112012006184B1/pt active IP Right Grant
- 2010-09-14 UA UAA201204827A patent/UA107582C2/ru unknown
- 2010-09-14 PE PE2012000342A patent/PE20121478A1/es not_active Application Discontinuation
- 2010-09-14 ME MEP-2017-134A patent/ME02765B/me unknown
- 2010-09-14 DK DK10752585.9T patent/DK2477611T3/en active
- 2010-09-14 HU HUE10752585A patent/HUE032963T2/en unknown
- 2010-09-14 ES ES10752585.9T patent/ES2625731T3/es active Active
- 2010-09-14 NZ NZ617025A patent/NZ617025A/en unknown
- 2010-09-14 CA CA2772275A patent/CA2772275A1/en not_active Abandoned
- 2010-09-14 UA UAA201409985A patent/UA115979C2/uk unknown
- 2010-09-14 US US13/395,586 patent/US20120172427A1/en not_active Abandoned
- 2010-09-14 RS RS20170589A patent/RS56074B1/sr unknown
- 2010-09-14 RU RU2012115459/15A patent/RU2012115459A/ru unknown
- 2010-09-14 AU AU2010297357A patent/AU2010297357B2/en active Active
- 2010-09-14 CN CN201510052347.5A patent/CN104666272A/zh active Pending
- 2010-09-14 LT LTEP10752585.9T patent/LT2477611T/lt unknown
- 2010-09-14 JP JP2012529234A patent/JP2013505213A/ja not_active Abandoned
- 2010-09-14 MY MYPI2012000646A patent/MY155613A/en unknown
- 2010-09-14 KR KR1020127006940A patent/KR101547880B1/ko active IP Right Grant
- 2010-09-14 PT PT107525859T patent/PT2477611T/pt unknown
- 2010-09-14 RU RU2015151938A patent/RU2681079C2/ru active
- 2010-09-14 CN CN201080041529.8A patent/CN102596184B/zh active Active
- 2010-09-14 CR CR20170078A patent/CR20170078A/es unknown
- 2010-09-14 SM SM20170299T patent/SMT201700299T1/it unknown
- 2010-09-14 CN CN201510052300.9A patent/CN104666238B/zh not_active Ceased
- 2010-09-14 EP EP10752585.9A patent/EP2477611B1/en not_active Revoked
- 2010-09-14 WO PCT/EP2010/063439 patent/WO2011032929A1/en active Application Filing
- 2010-09-16 AR ARP100103381A patent/AR078383A1/es not_active Application Discontinuation
- 2010-09-16 TW TW103142089A patent/TWI522130B/zh active
- 2010-09-16 JO JOP/2010/0317A patent/JO3327B1/ar active
- 2010-09-16 UY UY0001032889A patent/UY32889A/es not_active Application Discontinuation
- 2010-09-16 TW TW99131364A patent/TWI468190B/zh active
2012
- 2012-02-10 TN TNP2012000061A patent/TN2012000061A1/en unknown
- 2012-03-05 IL IL218492A patent/IL218492A/en active IP Right Grant
- 2012-03-12 CR CR20120116A patent/CR20120116A/es unknown
- 2012-03-13 MA MA34687A patent/MA33585B1/fr unknown
- 2012-03-15 CO CO12045392A patent/CO6511244A2/es active IP Right Grant
- 2012-03-16 US US13/422,494 patent/US8802735B2/en active Active
- 2012-03-16 HN HN2012000576A patent/HN2012000576A/es unknown
- 2012-03-16 GT GT201200075A patent/GT201200075A/es unknown
- 2012-03-16 DO DO2012000070A patent/DOP2012000070A/es unknown
2013
- 2013-11-18 AU AU2013257516A patent/AU2013257516B2/en active Active
2014
- 2014-04-30 US US14/265,433 patent/US20140235888A1/en not_active Abandoned
2015
- 2015-01-08 CL CL2015000047A patent/CL2015000047A1/es unknown
- 2015-07-16 HK HK15106786.8A patent/HK1206245A1/xx unknown
- 2015-07-16 HK HK15106785.9A patent/HK1206244A1/xx unknown
2016
- 2016-03-28 IL IL244809A patent/IL244809B/en active IP Right Grant
- 2016-10-11 US US15/290,677 patent/US20170247319A1/en not_active Abandoned
2017
- 2017-06-13 HR HRP20170904TT patent/HRP20170904T1/hr unknown
- 2017-07-04 CY CY20171100710T patent/CY1119364T1/el unknown
2018
- 2018-08-20 US US15/999,565 patent/US20190241505A1/en not_active Abandoned
2019
- 2019-02-19 IL IL26491219A patent/IL264912B/en active IP Right Grant

Also Published As

Publication number	Publication date
TW201117838A (en)	2011-06-01
PE20121478A1 (es)	2012-11-12
IL218492A0 (en)	2012-04-30
CN104666238B (zh)	2018-04-06
JP2013505213A (ja)	2013-02-14
TWI522130B (zh)	2016-02-21
RU2012115459A (ru)	2013-10-27
HUE032963T2 (en)	2017-11-28
AU2010297357B2 (en)	2013-11-07
NZ598744A (en)	2013-11-29
CN102596184A (zh)	2012-07-18
AU2013257516B2 (en)	2015-09-17
US20190241505A1 (en)	2019-08-08
TN2012000061A1 (en)	2013-09-19
CR20120116A (es)	2012-06-15
IL244809B (en)	2019-03-31
RS56074B1 (sr)	2017-10-31
IL244809A0 (en)	2016-04-21
CL2015000047A1 (es)	2015-06-12
CN104666272A (zh)	2015-06-03
RU2015151938A (ru)	2019-01-15
CO6511244A2 (es)	2012-08-31
HK1206245A1 (en)	2016-01-08
KR20120089461A (ko)	2012-08-10
AU2010297357A1 (en)	2012-04-05
BR112012006184A2 (pt)	2016-05-31
PE20152031A1 (es)	2016-01-14
US20170247319A1 (en)	2017-08-31
PT2477611T (pt)	2017-06-05
CY1119364T1 (el)	2018-02-14
UA107582C2 (uk)	2015-01-26
DK2477611T3 (en)	2017-07-10
ES2625731T3 (es)	2017-07-20
KR101547880B1 (ko)	2015-08-27
SI2477611T1 (sl)	2017-07-31
RU2681079C2 (ru)	2019-03-04
CN104739821B (zh)	2018-04-06
CN102596184B (zh)	2015-03-11
US20140235888A1 (en)	2014-08-21
MX336663B (es)	2016-01-27
CR20170078A (es)	2017-05-22
CN104666238A (zh)	2015-06-03
HRP20170904T1 (hr)	2017-09-08
IL218492A (en)	2016-04-21
NZ617025A (en)	2014-03-28
US20120172427A1 (en)	2012-07-05
EP2477611B1 (en)	2017-04-05
HN2012000576A (es)	2015-01-26
WO2011032929A1 (en)	2011-03-24
MX2012003122A (es)	2012-04-10
EP2477611A1 (en)	2012-07-25
US8802735B2 (en)	2014-08-12
UY32889A (es)	2011-04-29
LT2477611T (lt)	2017-06-26
IL264912B (en)	2019-11-28
GT201200075A (es)	2014-05-14
JO3327B1 (ar)	2019-03-13
BR112012006184B1 (pt)	2022-10-18
CN104739821A (zh)	2015-07-01
CA2772275A1 (en)	2011-03-24
TW201517935A (zh)	2015-05-16
MY155613A (en)	2015-11-13
MA33585B1 (fr)	2012-09-01
AR078383A1 (es)	2011-11-02
RU2015151938A3 (me)	2019-01-15
HK1206244A1 (en)	2016-01-08
TWI468190B (zh)	2015-01-11
DOP2012000070A (es)	2012-05-31
US20120208880A1 (en)	2012-08-16
UA115979C2 (uk)	2018-01-25
SMT201700299T1 (it)	2017-07-18
PL2477611T3 (pl)	2017-09-29

Publication	Publication Date	Title
ME02765B (me)	2018-01-20	(z)-2-cijan0-3-hidroksi-but-2-enske kiseline (4'-trifluormetilfenil) -amid formulacije tableta sa poboljšanom stabilnošću
BRPI0919447A2 (pt)	2015-12-15	derivados do ácido 1-amino-2-ciclobutiletilborônico
DK2308877T3 (da)	2014-04-22	Imidazopyridin-2-on-derivater
ECSP12011999A (es)	2012-07-31	Derivados benzamida sustituidos
DK2397480T3 (da)	2013-09-02	Diazepindionderivat
NO20083238L (no)	2010-01-25	Narresmokk
EP2413869A4 (en)	2014-12-17	PORTABLE ARTICLE
BRPI0823297A2 (pt)	2015-06-23	Garrafa
DK2275414T3 (da)	2015-06-22	Cyclopentylacrylamidderivat
HUE036071T2 (hu)	2018-06-28	Macitentánt tartalmazó terápiás készítmények
DK2387580T3 (da)	2014-10-13	Deoxyactagardinderivater
DE112008003753B8 (de)	2017-08-24	Reißverschluss
ATE534634T1 (de)	2011-12-15	2-phenyl-4-cyclopropyl-pyrimidinderivate
EP2475430A4 (en)	2013-05-15	GRANULATED ANTHELMINTIC PREPARATIONS AND OUTPUT SYSTEMS THEREFOR
DK2323933T3 (da)	2013-03-04	Stableenhed
EP2628733A4 (en)	2014-02-26	ACYLBENZEN DERIVATIVE
EP2593472A4 (en)	2014-01-08	STEM PROTEINS
BRPI1013017A2 (pt)	2016-03-29	"17beta-alquil-17alfa-óxi-estratrienos"
ES1072838Y (es)	2011-01-26	Posavaso
ATE516287T1 (de)	2011-07-15	Neuartige chromen-2-on-derivate
EE00876U1 (et)	2010-01-15	Orienteerumisv
UA18564S (uk)	2009-03-10	Тумбочка приліжкова
FI8597U1 (fi)	2010-01-27	Pelastuskanto-väline
IT1398148B1 (it)	2013-02-14	"auto-negozio"
FR2940753B3 (fr)	2010-12-31	L'eco-sapin